847results about How to "Good analgesic effect" patented technology

Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause said opioid analgesic to be released at a such a rate as to provide an analgesic effect after oral administration to a human patient for at least about 24 hours, and are characterized by providing an absorption half-life from 1 to about 8 hours. A method of titrating a human patient utilizing these sustained release opioid formulations is also disclosed.

1-phenyl-3-dimethylaminopropane compounds corresponding to the formula I

a method of preparing them, and the use of these substances as analgesic active ingredients in pharmaceutical compositions.

The invention relates to a 2-(2-(2, 6-dichlorophenyl amido) phenyl) methyl acetate, relative synthesis method and application, belonging to the technical field of chemical pharmacy, which comprises that adds acid into diclofenac salt to acidify the salt into diclofenac, reacts diclofenac with methanol, or adds acid into diclofenac salt to acidify the salt into diclofenac, to be reacted with chloracetyl chloride to obtain 2-(2-(2, 6-dichlorophenyl amido) phenyl) methyl acetate. The inventive drug has significant anti-inflammatory and analgesic effects.

The Chinese medicine oral preparation with the functions of warming channels, expelling pathogenic cold, removing dampness, promoting blood circulation, removing stasis, replenishing qi, nourishing blood, relieving rigidity of muscles and joints and stopping pain for curing acute and chronic osteoarthropathy and rheumatoid arthritis is made of 33 Chinese medicinal amterials of notopterygium root,pubescenjt angelica root, turmeria, Chinese angelica root, red peony root, astragalus root and others through the processes of proportioning, mixing and pulvering, rate.

To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound. The object has been attained by a condensed benzamide compound represented by the following formula (the symbols in the formula have the same meanings defined in the specification) or its salt:

The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific V_H, V_L, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.

Disclosed is a pharmaceutical composition, comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of celecoxib and/or at least one pharmaceutically acceptable salt thereof and oxycodone and/or at least one pharmaceutically acceptable salt thereof, said two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising orally administering to the patient an oral dosage form comprising two analgesic compounds consisting of celecoxib and/or at least one pharmaceutically acceptable salt thereof and oxycodone and/or at least one pharmaceutically acceptable salt thereof, said two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient.

The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R¹ is a C1-6 alkyl group which may be substituted, R² is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R³ is a hydrogen atom or a C1-6 alkyl group, R⁴ is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, and neuralgia.

Topical treatments for neuropathy are described. The treatments include topical formulations of NMDA antagonists and one additional active ingredient. In one example, the formulation includes ketamine and gabapentin for the treatment of a subject's neuropathy. These transdermal or topical compositions provide a surprising degree of effective relief from the symptoms of peripheral neuropathy and can be administered to subjects to treat various neuropathies.

The invention discloses compound benzocaine externally-applied medicinal liquid, gel or ointment. The medicine liquid, gel or ointment, which contains a compound medicine, is filled into an applicator to be applied on oral wound surfaces, ulcer surfaces and mucosa surfaces, treat tooth diseases, narcotize and relieve itching caused by haemorrhoids, treat itch and lubricate a nasopharyngeal catheter, inner root sight glass and the like for relieving pain.

Provided are pharmaceutical compositions and methods for the alleviation of pain in a patient with optimal ratios of morphine and oxycodone that provide superior analgesic efficacy and lower incidence of adverse side effects compared to morphine and oxycodone alone. The pharmaceutical compositions comprise morphine and oxycodone, or pharmaceutically acceptable salts thereof, in ratios of about 3 to 2 to about 1 to 2, morphine to oxycodone by weight.

The invention synthesizes four novel endomorphin-1 analogs, and belongs to the technical field of biochemistry. The endomorphin-1 analogs are prepared by performing N-end guanidyl formation at the first-position Tyr of endomorphin-1, replacing the second-position Pro by D-Ala, replacing the third-position Trp by Gly, and replacing the fourth-position Phe by Trp or performing para-position chlorination and fluorination modification or no modification on a benzene ring of Phe. The synthesized endomorphin-1 analogs are subjected to a series of physiological and pharmacological activity identification such as radio-ligand receptor binding assays, isolated organ bioactivity identification experiments, isolated enzymolysis stability experiments, analgesic tests with water bath and medicine tolerance experiments, show high affinity activity, high enzymolysis stability and high analgesic activity, and hardly cause tolerance. Therefore, the four novel endomorphin-1 analogs can be used for preparing clinical analgesic medicines.

Apparatus for providing transcutaneous electrical nerve stimulation (TENS) therapy to a user, the apparatus comprising: a housing; an application unit for providing mechanical coupling between the housing and the user's body; a stimulation unit for electrically stimulating at least one nerve of the user; a sensing unit for sensing the user's body movement and body orientation; and a reporting unit for providing the user with feedback based on the user's sensed body movement and body orientation.

The invention relates to a traditional Chinese medicine volatile oil composition for treating gastrointestinal dysfunction or irritable bowel syndrome (IBS), and a preparation method and applications thereof in the preparation of medicaments. The traditional Chinese medicine volatile oil composition is characterized by comprising the following components in parts by weight: 0-3 parts of patchouli volatile oil, 0-4 parts of atractylodes macrocephala volatile oil and 0-8 parts of orange peel volatile oil, wherein the parts of at least two components by weight are greater than 0. In the preferable scheme, the content of patchoulenone or patchouli alcohol accounts for 4-55% of the total content of the traditional Chinese medicine volatile oil composition; the content of atractylone accounts for 8-65% of the total content of the traditional Chinese medicine volatile oil composition, and the content of D-limonene accounts for 15-75% of the total content of the traditional Chinese medicine volatile oil composition. Compared with the compound crude extract, the traditional Chinese medicine volatile oil composition of the invention has a qualitative leap. The traditional Chinese medicine volatile oil composition can gather effective components, enhance the pharmacological action and the clinical curative effect, reduce the clinical dosage and be beneficial to enhancing quality control level.

The utility model discloses an adhesive plaster for skin and a use method. The adhesive plaster comprises a fabric layer, a plaster layer and a protecting layer that are sequentially superposed and arranged, wherein the fabric layer elastically stretches along length stretching direction and is not elastic in width direction; the plaster is evenly distributed on the inside surface of the fabric layer, and the plaster takes the shape of continuous strap and is arranged at intervals along width direction; and the protecting layer is release paper or release film. In virtue of the sticky elastic property of the plaster layer and the mechanical direction of the fabric layer and in combination with the principles of kinesiology and biomechanics to influence the trend of skin and increase the gap between skin and muscle, the adhesive plaster further promotes the lymph and blood circulation, removes a number of fatigue metabolic substances in vivo, pain products, metabolic substances remaining after inflammatory reaction, small inner haemorrhage and the like, and achieves the purposes of relieving pain, slowing down inflammation, speeding up recovery and avoiding harm. The treatment process is suitable for all parts on the body surface, and widely applicable to various groups of people.

The invention discloses novel application of a nano material. The novel application is in the preparation of tumor vascular occlusion agent. The nano material has the following properties: (1) surface hydrophilicity is provided; (2) surface electronegativity is provided; (3) the nano material with size between 50-250nm and rigidity can not easily pass the holes on tumor blood vessels and can be stuck in the holes; and (4) the material is able to absorb external radiation energy, internally transforms the energy into heat, and accumulates the heat, so that the morphology and structure of the nano material drastically change. During the treatment, the nano material is injected into tumor-bearing bodies, and then radiation is applied to the tumor site, so that the nano material absorbs radiation energy and the internal temperature rises rapidly; when the temperature is accumulated to a certain extent, the morphology and structure of the nano material change (explosion or rapid expansion of volume), resulting in change of morphological structure or function of tumor vascular endothelial cells, and destruction of the tumor blood vessels.